<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2709-7927</journal-id>
<journal-title><![CDATA[Acta Médica del Centro]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd centro]]></abbrev-journal-title>
<issn>2709-7927</issn>
<publisher>
<publisher-name><![CDATA[Hospital Provincial Clínico Quirúrgico Universitario Arnaldo Milián Castro]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2709-79272022000300504</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Carcinoma mamario HER2 positivo]]></article-title>
<article-title xml:lang="en"><![CDATA[HER2-positive breast carcinoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Pérez]]></surname>
<given-names><![CDATA[Raisel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llanes García]]></surname>
<given-names><![CDATA[Llanuris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Agüero Arboláez]]></surname>
<given-names><![CDATA[María del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Hernández]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Franco Rodón]]></surname>
<given-names><![CDATA[Alicia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alfonso González]]></surname>
<given-names><![CDATA[Carmen Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Villa Clara  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario &#8220;Celestino Hernández Robau&#8221;  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>16</volume>
<numero>3</numero>
<fpage>504</fpage>
<lpage>515</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2709-79272022000300504&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2709-79272022000300504&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2709-79272022000300504&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  la sobrexpresión de HER2 en el carcinoma mamario se asocia a una mayor actividad biológica del tumor y a un pronóstico desfavorable.  Objetivo:  determinar la incidencia de sobreexpresión pura del oncogén HER2/neu en carcinomas mamarios en el Hospital &#8220;Celestino Hernández&#8221; de la Provincia de Villa Clara y su relación con otras variables de valor pronóstico.  Métodos:  estudio descriptivo, retrospectivo realizado en el Hospital &#8220;Celestino Hernández&#8221; entre enero de 2017 y junio de 2019. Se incluyeron 293 mujeres con diagnóstico de carcinoma de mama infiltrante, a las biopsias se les realizó estudio inmunohistoquímico para determinar la incidencia de la sobreexpresión del oncogén HER2 y su relación con otras variables de valor pronóstico.  Resultados:  en la serie se encontraron 22 casos (7,5%) con sobreexpresión exclusiva del oncogén HER2/neu. De las pacientes con carcinomas con sobreexpresión de HER2 17 (77,3%) fueron mayores de 50 años, 20 (90,9%) tuvieron talla tumoral mayor de 2dos centímetros y 21 (95,45%) estuvieron asociadas al tipo histológico no especial (carcinoma ductal) del carcinoma mamario. Destaca la relación entre la sobreexpresión del oncogén HER2/neu con formas histológicas moderada y pobremente diferenciadas del carcinoma mamario. El índice de proliferación determinado por Ki67 fue mayor del 30% en 17 pacientes (77,27%).  Conclusión:  la edad posmenopáusica, el tipo histológico no especial, el grado histológico alto, los altos índices de Ki67 y la talla tumoral mayor de dos centímetros se asocian con frecuencia a la sobreexpresión de HER2 en carcinomas mamarios.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  HER2 overexpression in mammary carcinoma is associated to a higher biological activity of the tumor and to an unfavorable prognosis.  Objective:  to determine the incidence of pure overexpression of HER2/neu oncogene in mammary carcinomas in &#8220;Celestino Hernández&#8221; Hospital from Villa Clara Province and its relationship with other variables of prognostic value.  Methods:  descriptive, retrospective study was carried out at the &#8220;Celestino Hernández&#8221; Hospital between January 2017 and June 2019. It was included 293 women with diagnosis of infiltrating breast carcinoma, the biopsies were subjected to immunohistochemical study to determine the incidence of HER2 oncogene overexpression and its relationship with other variables of prognostic value.  Results:  22 cases (7.5%) with exclusive overexpression of the HER2/neu oncogene were found in the series. Of the patients with carcinomas with HER2 overexpression, 17 (77.3%) were older than 50 years, 20 (90.9%) had tumor size greater than 2 centimeters and 21 (95.45%) were associated with the non-special histological type (ductal carcinoma) of mammary carcinoma. The relationship between HER2/neu oncogene overexpression and moderately and poorly differentiated histological forms of mammary carcinoma stands out. The proliferation index determined by Ki67 was greater than 30% in 17 patients (77.27%).  Conclusion:  postmenopausal age, non-special histological type, high histological grade, high Ki67 indices and tumor size greater than two centimeters are frequently associated with HER2 overexpression in mammary carcinomas.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[neoplasia de la mama HER 2 positivo]]></kwd>
<kwd lng="es"><![CDATA[estudio inmunohistoquímico]]></kwd>
<kwd lng="en"><![CDATA[HER 2 positive breast neoplasms]]></kwd>
<kwd lng="en"><![CDATA[immunohistochemical study]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quevedo Gutiérrez]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Landa Fernández]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[García Barrera]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HER-2/neu en cáncer de mama localmente avanzado]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2016</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>108-15</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larios León]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[El estado de los receptores hormonales como factor pronóstico en pacientes con cáncer de mama HER2 positivos metastásicos recientemente diagnosticados en el Hospital Almanzor Aguinaga Asenjo durante el periodo 2016-2017]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Lambayeque ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional Pedro Ruiz Gallo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Vargas]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluar las tasas de recurrencia locorregional y a distancia de acuerdo a los subtipos moleculares por inmunohistoquímica tratadas con cirugía conservadora de mama, terapia sistémica, y/o bloqueo hormonal, +/- terapia anti HER2 y radioterapia para cáncer de mama temprano en el centro oncológico estatal ISSEMyM en el periodo de enero del 2011 a enero del 2016]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Toluca ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Autónoma del Estado de México]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Cokkinides]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Saslow]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Brawley]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2010</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-119</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2020]]></source>
<year>2020</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez Briones]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Cabrera]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Balderas Renteria]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Arredondo Espinoza]]></surname>
<given-names><![CDATA[EU]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto anticancerígeno in vitro de los siRNA ErbB2, IGF-1R y ITGB1 en células de cáncer de mama HER-2 positivo]]></article-title>
<source><![CDATA[RCFB]]></source>
<year>2019</year>
<edition>1</edition>
<page-range>25-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blows]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Driver]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Broeks]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[van Leeuwen]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Wesseling]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies]]></article-title>
<source><![CDATA[PLoS Med]]></source>
<year>2010</year>
<volume>7</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quirós Alpízar]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza Morales]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia a 5 años de pacientes con cáncer de mama triple negativo]]></article-title>
<source><![CDATA[Med Leg Costa Rica]]></source>
<year>2017</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-72</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Álvarez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Romo-Aguirre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz-de Iturbide]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama triple negativo: frecuencia y características en el Hospital Ángeles Pedregal]]></article-title>
<source><![CDATA[Acta Méd Grupo Ángeles]]></source>
<year>2017</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>269-74</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malvasio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schiavone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Camejo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Artagaveytia]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Di Matteo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínico-patológicas y evolución del cáncer de mama en mujeres uruguayas jóvenes]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2017</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>94-101</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<source><![CDATA[Robbins basic pathology]]></source>
<year>2013</year>
<edition>9</edition>
<page-range>178-9</page-range><publisher-loc><![CDATA[EUA ]]></publisher-loc>
<publisher-name><![CDATA[Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aparicio Cerna]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Perfil Epidemiológico de cáncer de mama HER-2 positivo en pacientes atendidos en el Hospital Nacional Hipólito Unanue entre Junio del 2012 a Junio del 2015]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Santiago de Surco ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Ricardo Palma]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunes dos Santos]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Superexpressão de HER-2 em carcinomas mamários femininos associada a lipid rafts e a lipogênese]]></article-title>
<source><![CDATA[Revista NBC Belo Horizonte]]></source>
<year>2016</year>
<volume>6</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>37-46</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fletscher Covaleda]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Inclusión del Pertuzumab al tratamiento habitual (Trastuzumab + Docetaxel) de mujeres con cáncer de mama metastásico HER2 positivo]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Santo Tomas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostinelli]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Mandó]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez de la Puente]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rivero]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Costanzo]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TDM-1 en cáncer de mama metastásico HER2 positivo. Experiencia institucional]]></article-title>
<source><![CDATA[Oncol Clín]]></source>
<year>2016</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>61-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrechea Irigoyen]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente García]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ibáñez Beroiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Córdoba Iturriagagoitia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santamaría Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guillén Grima]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subtipos moleculares del cáncer de mama: implicaciones pronósticas y características clínicas e inmunohistoquímicas]]></article-title>
<source><![CDATA[An Sist Sanit Navar]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>219-33</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boisserie Lacroix]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtevent-Labrot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferron]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lippa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bonnefoi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mac Grogan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation between imaging and molecular classification of breast cancers]]></article-title>
<source><![CDATA[Diagn Interv Imaging]]></source>
<year>2013</year>
<volume>94</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1069-80</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gamarra Manrique]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación de la sobre-expresión molecular del receptor HER2/neu (Human Epidermal Growth Factor Receptor 2/Neuro Glioblastoma) en cáncer de mama humano, mediante inmunohistoquímica por anticuerpos monoclonales, y su correlación pronóstica con el Sistema de Estadiaje TNM]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Arequipa ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de San Agustín de Arequipa]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Prichard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Handbook of Practical Immunohistochemistry. Frequently Asked Question]]></source>
<year>2015</year>
<edition>2</edition>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer Science+Business Media New York]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<collab>Programa Nacional de Consensos Inter-Sociedades</collab>
<article-title xml:lang=""><![CDATA[Factores pronósticos y predictivos en cáncer de mama temprano programa argentino de consensos de enfermedades oncológicas. Consenso nacional inter-sociedades]]></article-title>
<source><![CDATA[Rev Arg Mastol]]></source>
<year>2016</year>
<volume>36</volume>
<numero>128</numero>
<issue>128</issue>
<page-range>12-33</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cserni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histological type and typing of breast carcinomas and they WHO classification changes over time]]></article-title>
<source><![CDATA[Pathologica]]></source>
<year>2020</year>
<volume>112</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-41</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendoza del Solar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Echegaray]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Caso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil inmunohistoquímico del cáncer de mama en pacientes de un hospital general de Arequipa, Perú]]></article-title>
<source><![CDATA[Rev Med Hered]]></source>
<year>2015</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-4</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroga Echeverri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia neoadyuvante en pacientes con cáncer de mama localmente avanzado, basada en el esquema ciclofosfamida, doxorrubicina, taxanos con y sin trastuzumab, de acuerdo con la sobreexpresión de HER2]]></article-title>
<source><![CDATA[Rev Col Hematol Oncol]]></source>
<year>2020</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>34-42</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez Valle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Montesino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lores Hechevarria]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Azcuy]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez Hernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histología e inmunohistoquímica del cáncer de mama invasivo en la provincia de Pinar del Río]]></article-title>
<source><![CDATA[Rev Ciencias Médicas]]></source>
<year>2019</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez-Torres]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maycotte-González]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas Ruíz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la clasificación molecular por inmunohistoquímica en cáncer de mama avanzado tratado con epirubicina y docetaxel: diferencias clínicas, patológicas, terapéuticas y pronósticas]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>15-27</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Landaverde]]></surname>
<given-names><![CDATA[DU]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad de Trastuzumab en combinación con terapia sistémica en pacientes con cáncer de mama avanzados o metastásico HER2 positivos. Experiencia del Hospital México, Costa Rica]]></article-title>
<source><![CDATA[Rev Clin Esc Med]]></source>
<year>2017</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>28-39</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saenz Ladino]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<source><![CDATA[Expresión de receptores hormonales, HER 2 y KI 67 antes y después de quimioterapia neoadyuvante en mujeres con cáncer de mama ductal infiltrante]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Militar Nueva Granada]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spitale]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzola]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Soldini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzucchelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bordoni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2009</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>628-35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
